Novel highly efficient bladder cancer treatment with low toxicity
The ideal cancer treatment should combine great efficacy with high selectivity. The Swedish HAMLET Pharma AB develops revolutionary cancer treatments on a peptide-based platform for targeting and killing tumor cells with high precision. Their proprietary drug complex is derived from the human breast milk protein, alpha-lactalbumin, and represents a therapeutic solution with high tumor-killing capacity, high target specificity, no demonstrated toxicity, killing more than 40 different types of tumor cells. The EU-funded HAMLET-BC project will advance this drug complex in combination with the synthetic drug candidate Alpha1H into the clinical development pipeline as an early-stage treatment for bladder cancer, which has the highest recurrence rate among all cancer types.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeSME-2b - SME Instrument (grant only and blended finance)
211 33 Malmo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.